Literature DB >> 17646054

Endometrial carcinoma recurring as carcinosarcoma: report of two cases.

G Ferrandina1, G F Zannoni, E Martinelli, V Vellone, M G Prisco, G Scambia.   

Abstract

Endometrial carcinosarcoma is a rare, aggressive disease, accounting for approximately 3% of all uterine neoplasms. The emergence of sarcomatous elements is considered the evolution of subclones arising from high grade endometrial carcinomas. Here, we report two cases of primary endometrial carcinomas recurring as carcinosarcoma. Case 1. a 58-year-old postmenopausal woman diagnosed to have a poorly differentiated endometrial endometrioid adenocarcinoma (FIGO stage IB) developed an intra-abdominal recurrence of disease after 17 months from diagnosis. Histopathological analysis documented a biphasic neoplasia consisting of an epithelial (grade 3 endometrial endometrioid adenocarcinoma) and a sarcomatous component. Salvage chemotherapy with cisplatin, ifosfamide, epirubicin, and then with taxotere was attempted. The patient died after 2 months. Case 2. A 56-year-old woman with a diagnosis of grade 3 endometrial adenosquamous carcinoma of the endometrium (FIGO stage IIIA) experienced pelvic recurrence after five months from completion of chemotherapy. Definitive histology was malignant mixed mesodermal tumor with focal areas of chondrosarcomatous elements. The patient was triaged to exclusive concomitant chemoradiotherapy and salvage chemotherapy. The patient died after 3 months. We describe two cases of high grade endometrial carcinomas recurring as carcinosarcoma, thus providing evidence that the metaplastic sarcomatous evolution is a very rare event which can occur in patients with anaplastic endometrial cancer.

Entities:  

Mesh:

Year:  2007        PMID: 17646054     DOI: 10.1016/j.prp.2007.05.008

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  1 in total

1.  Mullerian carcinosarcoma in the colon of a patient with history of endometrial carcinoma: A case report and insight into possible pathogenesis.

Authors:  Claire Anne Therese Hemedez; Michele Lomme; M Ruhul Quddus
Journal:  Gynecol Oncol Rep       Date:  2018-09-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.